North Dakota

The key policy signal is SB 2064 itself. It was signed in Mar 2025 and altered North Dakota’s schedules, including the COMP360 placement in Schedule IV. That is important for policy watchers because it creates a state-federal mismatch on one named psilocybin formulation, but it is still much narrower than a medical-psilocybin law or service system.###

This source pass did not verify any North Dakota task force, advisory board, ballot measure, state implementation office, or local deprioritisation ordinance for psychedelics in the sources reviewed. The state is therefore best framed to frame North Dakota as legally conservative on access, with one narrow pharmaceutical scheduling development rather than a broad reform story.###

The clearest in-state ecosystem signal is commercial rather than clinical-service based. Lincoln Therapeutics lists manufacturing and packaging in Fargo, and 2025 North Dakota legislative testimony described the company as developing intranasal ketamine and esketamine, including work linked to Department of Defense partnerships. That is materially different from a local psilocybin clinic network or a state-sanctioned psychedelic therapy programme.###

This source pass did not verify a major North Dakota university or hospital classic-psychedelic trial hub from the sources reviewed in this source pass. The safest framing is that North Dakota’s verifiable psychedelic-adjacent activity sits closer to formulation, manufacturing, and controlled-substance scheduling than to human classical-psychedelic access or large visible trial infrastructure.###

Because North Dakota has not set up a regulated psilocybin-services model, there is no verified licensing stack for facilitators, service centres, manufacturers, training curricula, client-reporting systems, or public safety monitoring comparable to Oregon’s. The implementation machinery that does exist is the normal controlled-substances and pharmacy framework, plus whatever future regulatory consequences might follow from the state’s singular COMP360 scheduling provision.###

This means operational uncertainty is concentrated in future interpretation, not current service roll-out. A useful follow-up check is whether any North Dakota agency has issued guidance on the COMP360 scheduling amendment, because This source pass did not verify an implementation bulletin or rule package in the materials reviewed.###

North Dakota’s verified ecosystem is thin by comparison with research-heavy or reform-heavy states. The most concrete local presence I could verify is Lincoln Therapeutics’ Fargo footprint and related legislative testimony about intranasal ketamine/esketamine development.###

This source pass did not verify a materially developed in-state public ecosystem of psychedelic clinics, non-profits, recurring conferences, or university-centred classic-psychedelic collaborations. The page should therefore avoid implying a mature North Dakota psychedelic scene.###

Over the next 12 to 24 months, the most plausible North Dakota developments are interpretive rather than service-based. Watch for agency guidance, pharmacy-board interpretation, or developer activity tied to the COMP360 scheduling change. Unless federal and clinical-regulatory events move first, that state-level carve-out still looks more symbolic and preparatory than operational.###

Patient access is unlikely to change materially without either a new state access bill or a federal/FDA pathway that makes the North Dakota scheduling change more actionable. The more immediate monitor points are any expansion of ketamine/esketamine infrastructure, any formal agency commentary on SB 2064, and any visible in-state trial activity linked to Fargo-based manufacturing or developer partnerships.###